Compare PRG & KLRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRG | KLRA |
|---|---|---|
| Founded | 2020 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.7B |
| IPO Year | 2020 | 2026 |
| Metric | PRG | KLRA |
|---|---|---|
| Price | $32.47 | $11.29 |
| Analyst Decision | Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $50.00 | N/A |
| AVG Volume (30 Days) | 536.4K | ★ 927.7K |
| Earning Date | 04-29-2026 | N/A |
| Dividend Yield | ★ 1.45% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.80 | N/A |
| Revenue | ★ $2,409,223,000.00 | N/A |
| Revenue This Year | $23.77 | N/A |
| Revenue Next Year | $7.91 | N/A |
| P/E Ratio | $18.08 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $25.80 | $11.77 |
| 52 Week High | $47.73 | $23.82 |
| Indicator | PRG | KLRA |
|---|---|---|
| Relative Strength Index (RSI) | 22.77 | 29.27 |
| Support Level | $32.30 | N/A |
| Resistance Level | $33.81 | $19.15 |
| Average True Range (ATR) | 1.18 | 0.97 |
| MACD | -0.34 | -0.14 |
| Stochastic Oscillator | 5.35 | 3.87 |
PROG Holdings Inc is a financial technology holding company that provides transparent and competitive payment options to consumers. The company has two reportable segments: Progressive Leasing, an in-store, app-based, and e-commerce point-of-sale lease-to-own solutions provider; and Vive Financial (Vive), an omnichannel provider of second-look revolving credit products. The majority of the revenue of the company is earned through the Progressive Leasing segment.
Kailera Therapeutics Inc is a clinical-stage biotechnology company. The company focuses on developing a diversified pipeline to provide options for people living with obesity. The company is progressing four clinical-stage product candidates, leveraging multiple GLP-1 based mechanisms of action and routes of administration. The company's obesity-first approach seeks to advance product candidates with the potential to maximize weight loss and address critical needs in the current therapeutic landscape.